Consistent with previous findings in pancreatic cancer and leukaemia cells (Ougolkov et al, 2006, 2007), we found that pharmacologic inhibition of GSK-3β resulted in depletion of nuclear GSK-3β from the renal cancer cells' nuclei by 24 h of AR-A014418 treatment (Figure 4E). The gene discussed is GSK3B; the disease is renal carcinoma.